Subtitle
Comparison of the Effectiveness of Radiotherapy with 3D-CRT, IMRT, VMAT and PT for Newly Diagnosed Glioblastoma: A Bayesian Network Meta-Analysis.
Subtitle
Comparison of the Effectiveness of Radiotherapy with 3D-CRT, IMRT, VMAT and PT for Newly Diagnosed Glioblastoma: A Bayesian Network Meta-Analysis.
Proto therapy Time
December 2023
Executive summary
Based on six original studies including 816 glioblastoma multiforme patients, this comprehensive synthesis of data performed by a Bayesian network meta-analysis showed that PT demonstrated the highest probability of being associated with the best OS (SUCRA: 72.6%), followed by VMAT (SUCRA: 66.5%) and IMRT (SUCRA:44.9), whereas 3DCRT was least likely to be the optimal treatment strategy (SUCRA: 26.3%). PT was the most likely regimen yielding a higher PFS with estimated SUCRA values of 78.25%, followed by IMRT with 57%.
Top cancer treatments
Related contents
Proton Therapy Publication
November 2020
Comparing bowel and urinary domains of patient-reported quality of life at the end of and 3 months post radiotherapy between intensity-modulated radiotherapy and proton beam therapy for clinically localized prostate cancer.
Proton Therapy Publication
October 2023
Comparing the oncologic outcomes of proton therapy and intensity-modulated radiation therapy for head and neck squamous cell carcinoma.
Proton Therapy Publication
January 2024
Proton and photon radiotherapy in stage III NSCLC: Effects on hematological toxicity and adjuvant immune therapy.
Proton Therapy Publication
July 2023
Long-term outcomes of modern multidisciplinary management of sinonasal cancers: The M. D. Anderson experience.
Proton Therapy Publication
November 2022
Pattern of Radiotherapy Treatment in Low-Risk, Intermediate-Risk, and High-Risk Prostate Cancer Patients: Analysis of National Cancer Database.
Proton Therapy Publication
August 2022
Cardiopulmonary Toxicity Following Intensity-Modulated Proton Therapy (IMPT) Versus Intensity-Modulated Radiation Therapy (IMRT) for Stage III Non-Small Cell Lung Cancer.
Proton Therapy Publication
October 2022
High-dose Intensity-modulated proton therapy versus Standard-dose Intensity-modulated RadIation therapy for esophageal squamous cell carcinoma (HI-SIRI): study protocol for a randomized controlled clinical trial.
Proton Therapy Publication
October 2022
Systematic Review for Deep Inspiration Breath Hold in Proton Therapy for Mediastinal Lymphoma: A PTCOG Lymphoma Subcommittee Report and Recommendations.
Proton Therapy Publication
November 2022
Toxicity Profiles and Survival Outcomes Among Patients With Nonmetastatic Oropharyngeal Carcinoma Treated With Intensity-Modulated Proton Therapy vs Intensity-Modulated Radiation Therapy.